Intermediate follow-up results from the multicenter engager European pivotal trial

TY - JOUR

T1 - Intermediate follow-up results from the multicenter engager European pivotal trial

AU - Holzhey, David

AU - Linke, Axel

AU - Treede, Hendrik

AU - Baldus, Stephan

AU - Bleiziffer, Sabine

AU - Wagner, Anke

AU - Börgermann, Jochen

AU - Scholtz, Werner

AU - Vanoverschelde, Jean-Louis

AU - Falk, Volkmar

N1 - Copyright © 2013 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

PY - 2013/12

Y1 - 2013/12

N2 - BACKGROUND: Optimal transcatheter aortic valve (TAVI) results require accurate valve positioning, including anatomically correct orientation and secure fixation within the aortic annulus, thereby potentially decreasing paravalvular regurgitation. The new Engager (Medtronic 3F Therapeutics, Santa Ana, CA) transapical valve system captures the native leaflets for sealing and allows for tactile feedback during valve placement. We report initial safety and performance outcomes of the Engager system through 6 months in patients with severe aortic valve stenosis at high risk for surgical aortic valve replacement.METHODS: An interim analysis was performed on the first 61 enrolled September 2011 through May 2012. Inclusion criteria comprised severe aortic stenosis, New York Heart Association functional class of II or greater, logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) of 20% or greater, or contraindication to surgical aortic valve replacement. The primary endpoint was all-cause mortality at 30 days. Patients were evaluated 24 to 48 hours post-procedure, at hospital discharge, 30 days and 6 months. Follow-up is planned annually through five years.RESULTS: Baseline characteristics for the 61 patients were mean age 81.9 ± 4.4 years, 62.3% female, 88.5% New York Heart Association class III/IV, 52.5% coronary artery disease, and 54.2% extracardiac arteriopathy. For all of the attempted implantations (n = 60), the Engager prosthesis was positioned in the correct anatomic position without conversions to surgery, second valve implantation, device malposition, aortic annular rupture, or coronary obstruction. All-cause mortality was 9.9% at 30 days and 16.9% at 6 months. The baseline mean aortic valve gradient was 43.7 ± 16.7 mm Hg and 11.5 ± 5.0 mm Hg at 30 days, and showed similar reduction at 6 months (13.9 ± 6.2 mm Hg). There was no paravalvular regurgitation greater than mild through 6 months.CONCLUSIONS: Early postoperative results support implantation success and valve safety. Analysis for 6 month outcomes shows stable hemodynamic performance and clinical outcome. (Transapical Implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System-the Engager European Pivotal Trial; NCT01348438).

AB - BACKGROUND: Optimal transcatheter aortic valve (TAVI) results require accurate valve positioning, including anatomically correct orientation and secure fixation within the aortic annulus, thereby potentially decreasing paravalvular regurgitation. The new Engager (Medtronic 3F Therapeutics, Santa Ana, CA) transapical valve system captures the native leaflets for sealing and allows for tactile feedback during valve placement. We report initial safety and performance outcomes of the Engager system through 6 months in patients with severe aortic valve stenosis at high risk for surgical aortic valve replacement.METHODS: An interim analysis was performed on the first 61 enrolled September 2011 through May 2012. Inclusion criteria comprised severe aortic stenosis, New York Heart Association functional class of II or greater, logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) of 20% or greater, or contraindication to surgical aortic valve replacement. The primary endpoint was all-cause mortality at 30 days. Patients were evaluated 24 to 48 hours post-procedure, at hospital discharge, 30 days and 6 months. Follow-up is planned annually through five years.RESULTS: Baseline characteristics for the 61 patients were mean age 81.9 ± 4.4 years, 62.3% female, 88.5% New York Heart Association class III/IV, 52.5% coronary artery disease, and 54.2% extracardiac arteriopathy. For all of the attempted implantations (n = 60), the Engager prosthesis was positioned in the correct anatomic position without conversions to surgery, second valve implantation, device malposition, aortic annular rupture, or coronary obstruction. All-cause mortality was 9.9% at 30 days and 16.9% at 6 months. The baseline mean aortic valve gradient was 43.7 ± 16.7 mm Hg and 11.5 ± 5.0 mm Hg at 30 days, and showed similar reduction at 6 months (13.9 ± 6.2 mm Hg). There was no paravalvular regurgitation greater than mild through 6 months.CONCLUSIONS: Early postoperative results support implantation success and valve safety. Analysis for 6 month outcomes shows stable hemodynamic performance and clinical outcome. (Transapical Implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System-the Engager European Pivotal Trial; NCT01348438).

KW - Aged

KW - Aged, 80 and over

KW - Aortic Valve Stenosis/diagnostic imaging

KW - Cardiac Catheterization/methods

KW - Cause of Death/trends

KW - Echocardiography

KW - Feasibility Studies

KW - Female

KW - Follow-Up Studies

KW - Germany/epidemiology

KW - Heart Valve Prosthesis Implantation/methods

KW - Heart Ventricles/diagnostic imaging

KW - Humans

KW - Male

KW - Retrospective Studies

KW - Survival Rate/trends

KW - Time Factors

KW - Treatment Outcome

KW - Ventricular Function, Left/physiology

U2 - 10.1016/j.athoracsur.2013.06.089

DO - 10.1016/j.athoracsur.2013.06.089

M3 - SCORING: Journal article

C2 - 24021766

VL - 96

SP - 2095

EP - 2100

JO - ANN THORAC SURG

JF - ANN THORAC SURG

SN - 0003-4975

IS - 6

ER -